- Home
- ENLT vs VERA Comparison
ENLT vs VERA Comparison
Compare ENLT & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENLT
- VERA
- Stock Information
- Founded
- ENLT 2008
- VERA 2016
- Country
- ENLT Israel
- VERA United States
- Employees
- ENLT N/A
- VERA N/A
- Industry
- ENLT
- VERA Biotechnology: Pharmaceutical Preparations
- Sector
- ENLT
- VERA Health Care
- Exchange
- ENLT Nasdaq
- VERA Nasdaq
- Market Cap
- ENLT 2.0B
- VERA 1.6B
- IPO Year
- ENLT 2023
- VERA 2021
- Fundamental
- Price
- ENLT $19.50
- VERA $18.95
- Analyst Decision
- ENLT Buy
- VERA Buy
- Analyst Count
- ENLT 3
- VERA 8
- Target Price
- ENLT $19.67
- VERA $64.00
- AVG Volume (30 Days)
- ENLT 28.0K
- VERA 1.3M
- Earning Date
- ENLT 05-06-2025
- VERA 05-06-2025
- Dividend Yield
- ENLT N/A
- VERA N/A
- EPS Growth
- ENLT 90.47
- VERA N/A
- EPS
- ENLT 0.98
- VERA N/A
- Revenue
- ENLT $397,296,000.00
- VERA N/A
- Revenue This Year
- ENLT $355.90
- VERA N/A
- Revenue Next Year
- ENLT $42.83
- VERA N/A
- P/E Ratio
- ENLT $19.18
- VERA N/A
- Revenue Growth
- ENLT 44.42
- VERA N/A
- 52 Week Low
- ENLT $14.01
- VERA $18.53
- 52 Week High
- ENLT $20.19
- VERA $51.61
- Technical
- Relative Strength Index (RSI)
- ENLT 62.94
- VERA 35.84
- Support Level
- ENLT $16.87
- VERA $18.76
- Resistance Level
- ENLT $20.19
- VERA $20.21
- Average True Range (ATR)
- ENLT 0.63
- VERA 0.90
- MACD
- ENLT 0.05
- VERA -0.16
- Stochastic Oscillator
- ENLT 79.26
- VERA 4.46
About ENLT Enlight Renewable Energy Ltd.
Enlight Renewable Energy Ltd develops, finances, constructs, owns, and operates utility-scale renewable energy projects. The company's operating segments are the MENA segment, Europe segment, U.S.A segment, and Others. It generates the majority of its revenue from the Europe segment, which produces its revenue from the sale of the electricity that is produced through wind energy and solar energy in Europe.
About VERA Vera Therapeutics Inc.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.